Orchestra BioMed (NASDAQ:OBIO) Stock: Insider Eric Fain Buys 20,000 Shares

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO – Get Free Report) Director Eric Fain acquired 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were bought at an average price of $5.00 per share, with a total value of $100,000.00. Following the completion of the transaction, the director directly owned 119,630 shares in the company, valued at approximately $598,150. The trade was a 20.07% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Orchestra BioMed Price Performance

OBIO stock traded up $0.02 on Monday, reaching $5.70. The company had a trading volume of 781,799 shares, compared to its average volume of 290,898. The company has a debt-to-equity ratio of 1.80, a quick ratio of 8.24 and a current ratio of 8.26. Orchestra BioMed Holdings, Inc. has a 1 year low of $3.46 and a 1 year high of $6.50. The company’s fifty day moving average is $5.74 and its 200 day moving average is $4.57. The company has a market cap of $342.60 million, a P/E ratio of -6.71 and a beta of 0.56.

Orchestra BioMed (NASDAQ:OBIO – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.01. The business had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.14 million. Orchestra BioMed had a negative return on equity of 149.61% and a negative net margin of 184.60%. On average, research analysts forecast that Orchestra BioMed Holdings, Inc. will post -1.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

OBIO has been the topic of a number of recent research reports. Weiss Ratings upgraded shares of Orchestra BioMed from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. Chardan Capital reiterated a “buy” rating and set a $20.00 price target on shares of Orchestra BioMed in a report on Friday, October 23rd. Piper Sandler reiterated an “overweight” rating on shares of Orchestra BioMed in a report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Orchestra BioMed in a research report on Monday, October 5th. Finally, B. Riley Financial upped their price objective on shares of Orchestra BioMed from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, September 15th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $13.17.

Get Our Latest Analysis on OBIO

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Orchestra BioMed during the second quarter worth $10,832,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Orchestra BioMed in the second quarter valued at $2,771,000. Rice Hall James & Associates LLC purchased a new stake in shares of Orchestra BioMed in the second quarter valued at $1,830,000. Flat Footed LLC acquired a new position in Orchestra BioMed in the second quarter valued at $1,084,670. Finally, Knott David M Jr increased its stake in Orchestra BioMed by 1.5% in the first quarter. Knott David M Jr now owns 253,651 shares of the company’s stock valued at $1,078,000 after purchasing an additional 3,651 shares during the last quarter. Hedge funds and other institutional investors own 53.20% of the company’s stock.

About Orchestra BioMed

(Get Free Report)

Orchestra BioMed Holdings, Inc is a clinical-stage biotechnology and medical device company focused on developing technologies for cardiovascular disease and other high-need medical conditions. The company uses a partnership-driven business model, collaborating with established medical device and healthcare companies to advance products through clinical development and toward commercialization.

Its lead program is BackBeat Cardiac Neuromodulation Therapy, an investigational bioelectronic treatment intended to provide sustained reductions in blood pressure for patients with hypertension.

Featured Articles

Insider Buying and Selling by Quarter for Orchestra BioMed (NASDAQ:OBIO)

Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.